Skip to main content

Laila Asskour

Institutions of which they are part

Research technician
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Laila Asskour

Institutions of which they are part

Research technician
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Projects

CHRONOS – Cronificación de la migraña: estudio longitudinal multi-ómico para la detección temprana, diagnóstico y prevención.

IP: Patricia Pozo Rosich
Collaborators: Laila Asskour , Eulalia Gine Cipres, Victor José Gallardo Lopez, Rut Mas deles Valls Cierco, Laura Gómez Dabó
Funding agency: Instituto de Salud Carlos III
Funding: 183750
Reference: PI25/01561
Duration: 01/01/2026 - 31/12/2028

MIGRANOSTIC: Estandardització d’un procediment diagnòstic molecular per a la migranya mitjançant biomarcadors de miARN

IP: Patricia Pozo Rosich
Collaborators: Laila Asskour , Eulalia Gine Cipres, Anna Cristina Segú Cristina, Victor José Gallardo Lopez, Edoardo Caronna
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 64938.52
Reference: SLT041/25/000055
Duration: 04/12/2025 - 03/12/2026

Assessing the role of glial cells in migraine and its chronification

IP: Marta Vila Pueyo
Collaborators: Laila Asskour , Victor José Gallardo Lopez, Erika Ivanna Araya
Funding agency: Ministerio Ciencia, Innovación y Universidades
Funding: 175000
Reference: PID2022-137287NA-I00
Duration: 01/09/2023 - 31/08/2027

Ministerio de Ciencia

Biomarcadores neuroinflamatorios en pacientes con migraña: prueba de concepto para el diagnóstico molecular de la enfermedad

IP: Marta Vila Pueyo
Collaborators: Laila Asskour , Patricia Pozo Rosich, Victor José Gallardo Lopez, Otilia Gliga
Funding agency: Fundación Eugenio Rodríguez Pascual
Funding: 24990
Reference: FERP-2023-MVP
Duration: 17/01/2024 - 16/01/2026

Related news

On April 18 and 19, the Vall d’Hebron Research Institute (VHIR) will once again join the Science Festival 2026 with a diverse and participatory program focused on health, innovation, and citizen engagement in research.

The treatment with fremanezumab becomes the first approved therapy to demonstrate efficacy in children and adolescents, a key stage of life as it is one of the most disabling and concentrates the peak incidence of the disease.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Patricia Picallo Ramos

Patricia Picallo Ramos

Research technician
Nephrology and kidney transplantation
Read more
Julian Piñeiro Fernandez

Julian Piñeiro Fernandez

Research technician
Translational Molecular Pathology
Read more
Maria Morillo Soriano

Maria Morillo Soriano

Research assistant
Growth and Development
Read more
Pere Nubiola Rivera

Pere Nubiola Rivera

Research assistant
Rheumatology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.